Appointed to this Advisory Board to offer my expertise in evaluating and assessing the company's launch preparations, commercialization strategies, and medical affairs initiatives. By leveraging my extensive cell therapy experience in both oncology and autoimmune disease, and my background in autologous CAR-T launch activities, I aim to provide valuable counsel to the company's executives and the broader launch team to assist in ensuring a highly successful launch.

ONK Therapeutics is dedicated to optimizing a next generation of off-the-shelf, dual-targeted NK cell therapies for patients with hematologic and solid cancers.The company’s proprietary NK cell therapy platform is based on a dual-targeted construct, combining a chimeric antigen receptor (CAR) targeting a known tumor antigen, with a TRAIL variant targeting the death receptor pathway through DR4 or DR5. This dual-targeted approach has the potential to improve efficacy and be less vulnerable to antigen escape.This platform could be broadly applicable across a wide range of targets and tumor types, with the potential to bring significant therapeutic benefit.

Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders.At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.

Genomic Health, a life science company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions.

Publicly traded biotech company, focussed on early clinical development of oncology drug candidates. Lead candidate was RP101, a nucleoside analogue under investigation as an adjunct to chemotherapy in the treatment of patients with pancreatic cancer. RP101 was successfully out-licensed to SciClone Pharmaceuticals, Inc., Foster City, CA.